129 related articles for article (PubMed ID: 18392006)
1. Amgen's Japan deal.
Ratner M
Nat Biotechnol; 2008 Apr; 26(4):366. PubMed ID: 18392006
[No Abstract] [Full Text] [Related]
2. Roche and Igen in shotgun wedding.
Bouchie A
Nat Biotechnol; 2003 Sep; 21(9):958. PubMed ID: 12949542
[No Abstract] [Full Text] [Related]
3. The closure of Sugen.
Levitzki A
Nat Biotechnol; 2003 Sep; 21(9):969. PubMed ID: 12949548
[No Abstract] [Full Text] [Related]
4. A license to print money?
Nat Biotechnol; 2006 Jun; 24(6):593. PubMed ID: 16763570
[No Abstract] [Full Text] [Related]
5. Value creation and sharing among universities, biotechnology and pharma.
Edwards MG; Murray F; Yu R
Nat Biotechnol; 2003 Jun; 21(6):618-24. PubMed ID: 12776145
[No Abstract] [Full Text] [Related]
6. Goodbye Columbus! New NRDOs forego discovery.
Thiel KA
Nat Biotechnol; 2004 Sep; 22(9):1087-92. PubMed ID: 15340473
[No Abstract] [Full Text] [Related]
7. Amgen's NESP victory cuts out Johnson & Johnson.
Fürst I
Nat Biotechnol; 1999 Feb; 17(2):124. PubMed ID: 10052335
[No Abstract] [Full Text] [Related]
8. GlaxoSmithKline, Pfizer to merge HIV drug units in new company.
AIDS Read; 2009; 19(6):206. PubMed ID: 19642236
[No Abstract] [Full Text] [Related]
9. Can 'double blockbuster' strengthen Amgen's backbone?
Sheridan C
Nat Biotechnol; 2008 Apr; 26(4):361-3. PubMed ID: 18391999
[No Abstract] [Full Text] [Related]
10. Genomics companies shop around for chemical expertise.
Fletcher L
Nat Biotechnol; 2004 Feb; 22(2):137-8. PubMed ID: 14755277
[No Abstract] [Full Text] [Related]
11. Sugen falls as casualty of Pfizer-Pharmacia merger.
Garber K
Nat Biotechnol; 2003 Jul; 21(7):722-3. PubMed ID: 12833079
[No Abstract] [Full Text] [Related]
12. Changing partners.
Nat Biotechnol; 2002 Sep; 20(9):855. PubMed ID: 12205487
[No Abstract] [Full Text] [Related]
13. Deal-making trends in oncology.
Moore K; Walker J
Nat Rev Drug Discov; 2009 Aug; 8(8):604. PubMed ID: 19644466
[No Abstract] [Full Text] [Related]
14. A special biotech speculation.
Jacobs T
Nat Biotechnol; 2006 Jun; 24(6):622. PubMed ID: 16763586
[No Abstract] [Full Text] [Related]
15. Value drivers in licensing deals.
Arnold K; Coia A; Saywell S; Smith T; Minick S; Löffler A
Nat Biotechnol; 2002 Nov; 20(11):1085-9. PubMed ID: 12410249
[No Abstract] [Full Text] [Related]
16. Amgen's big-ticket play for Immunex.
Fletcher L
Nat Biotechnol; 2002 Feb; 20(2):105-6. PubMed ID: 11821840
[No Abstract] [Full Text] [Related]
17. No pain, no gain?
Jacobs T
Nat Biotechnol; 2005 Aug; 23(8):934. PubMed ID: 16082357
[No Abstract] [Full Text] [Related]
18. Great company, bad stock.
Jacobs T
Nat Biotechnol; 2005 Feb; 23(2):173. PubMed ID: 15696142
[No Abstract] [Full Text] [Related]
19. When your stock takes a nosedive.
Jacobs T
Nat Biotechnol; 2006 Feb; 24(2):144. PubMed ID: 16465152
[No Abstract] [Full Text] [Related]
20. Roger Perlmutter on shaping Amgen's R&D strategy. Interview by Christopher Watson.
Perlmutter RM
Drug Discov Today; 2005 Jun; 10(11):745-8. PubMed ID: 15922930
[No Abstract] [Full Text] [Related]
[Next] [New Search]
